Johnson & Johnson, ICOTYDE, Icotrokinra, Plaque Psoriasis, IL-23R, Oral Peptide, Dermatology, Immunology, ICONIC-TOTAL, EADV 2026, Phase 3

Spring House, Pennsylvania, U.S., October 2, 2026 Johnson & Johnson announced new two-year results for ICOTYDE® (icotrokinra) from the...